Cohort Studyhigh evidence
Large-scale proteomics across neurological disorders uncovers biomarker panel and targets in multiple sclerosis.
Cell·April 2, 2026·PMID 41747728
Why it mattersCurrent MS biomarkers lack specificity for challenging differential diagnoses. This validated 22-protein CSF panel offers improved diagnostic accuracy and may aid in staging disease progression, addressing a critical clinical need.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled